0001104659-23-115011.txt : 20231107 0001104659-23-115011.hdr.sgml : 20231107 20231107073127 ACCESSION NUMBER: 0001104659-23-115011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231107 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 231381580 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 8-K 1 tm2330023d1_8k.htm FORM 8-K
false 0001590560 00-0000000 0001590560 2023-11-07 2023-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 7, 2023

 

uniQure N.V.

(Exact Name of Registrant as Specified in Charter)

 

The Netherlands   001-36294   N/A
(State or Other
Jurisdiction of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

Paasheuvelweg 25a,
1105 BP Amsterdam, The Netherlands		   N/A
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +31-20-566-7394

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:

Ordinary Shares, par value €0.05 per share

   QURE   The Nasdaq Stock Market LLC
The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition

 

On November 7, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023, and highlighting company progress. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibit

 

Exhibit No. Description
   
99.1 Press Release of uniQure N.V. dated November 7, 2023 announcing third quarter 2023 financial results and highlights recent company progress.
   
104 Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UNIQURE N.V.
     
Date: November 7, 2023 By: /s/ Jeannette Potts
    Jeannette Potts
    Chief Legal and Compliance Officer

 

 

 

 EX-99.1 2 tm2330023d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

uniQure Announces Third Quarter 2023 Financial Results

and Highlights Recent Company Progress

 

~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in

refractory mesial temporal lobe epilepsy ~

 

~ On track to provide clinical update from U.S. and European Phase I/II trials of AMT-130 in

Huntington’s disease later in the fourth quarter of 2023 ~

 

~ uniQure and CSL win 2023 Prix Galien USA award for HEMGENIX® ~

 

~ Announced strategic reorganization to focus on advancing multiple clinical-stage programs and expect

to deliver $180 million of cost savings over the next three years ~

 

~ Strong cash position of approximately $660 million as of September 30, 2023 expected to

fund operations into the second quarter of 2027 ~

 

Lexington, MA and Amsterdam, the Netherlands, November 7, 2023 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2023 and highlighted recent progress across its business.

 

“In the third quarter we made significant progress towards our goal of advancing multiple clinical-stage programs and focusing resources to generate value from these important investments,” stated Matt Kapusta, chief executive officer of uniQure. “We are very pleased to have achieved FDA clearance of the IND for AMT-260 in refractory mesial temporal lobe epilepsy and look forward to initiating patient enrollment in the Phase I/IIa study as soon as possible. In addition, we are making good progress toward initiating patient screening for a Phase I/II trial of AMT-162 in SOD1-ALS and the submission of an IND for AMT-191 in Fabry disease. We also look forward to providing another clinical update later this quarter from our ongoing Phase I/II studies of AMT-130 in Huntington’s disease, which will include up to 2.5 years of patient follow-up.”

 

“As we prepare for 2024, we remain laser focused on execution across our portfolio of gene therapy product candidates with the goal of achieving clinical proof-of-concept as rapidly as possible. We also remain committed to carefully managing costs, prudently allocating capital, and thoughtfully evaluating strategies that can enhance value for shareholders in an increasingly challenging market environment.”

 

Recent Updates

 

  ·Advancing AMT-130 for the treatment of Huntington’s disease

 

·Later in the fourth quarter of 2023, the Company plans to provide a clinical update from the U.S. and European Phase I/II studies of AMT-130, including 18- and 30-month follow-up data from the treated patients in the high- and low-dose U.S. cohorts, respectively. The data update will include safety and tolerability, biomarker, imaging and functional data across both high and low-dose cohorts.

 

 

 

 

·A total of 33 patients have now been treated with AMT-130 across two dose cohorts in the U.S. and EU clinical trials. The Company recently initiated patient screening for a third cohort in up to 12 patients to further investigate both doses in combination with perioperative immunosuppression, with a focus on evaluating near-term safety and tolerability.

 

·In the first quarter of 2024, the Company plans to request regulatory interactions with the Food and Drug Administration (FDA) to discuss the U.S. and EU data and potential late-stage development pathways for AMT-130.

 

  ·Advancing additional programs into the clinic

 

·AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (rMTLE) – In the third quarter of 2023, the Company announced the clearance of an investigational new drug (IND) for the Phase I/IIa clinical study of AMT-260. Screening and patient enrollment is expected to begin in the fourth quarter of 2023 with first patient dosing planned to occur in the first quarter of 2024.

 

·AMT-162 for the treatment of SOD1 amyotrophic lateral sclerosis (ALS) - In January 2023, the Company entered into a global licensing agreement with Apic Bio for ABP-102, now AMT-162 for the treatment of superoxide dismutase 1 (SOD1) ALS, a rare, genetic form of ALS. The Company expects to initiate patient screening in the fourth quarter of 2023 with first patient dosing planned to occur in the first quarter of 2024.

 

·AMT-191 for the treatment of Fabry disease – The Company expects to submit an IND in the fourth quarter of 2023 and to begin patient dosing in 2024.

 

  ·Supporting the commercial launch of HEMGENIX® in the United States and European Union

 

·In October 2023, uniQure and CSL Behring LLC (“CSL”) announced that the companies received the 2023 Prix Galien USA Award in the category of Best Product for Rare/Orphan Diseases for HEMGENIX®. HEMGENIX® was one of several product nominations in this category. Created in 1970, the Prix Galien Awards recognizes outstanding innovation and scientific advancement and is regarded as the equivalent of the Nobel Prize for the life science industry.

 

·In July 2023, uniQure received a $100 million milestone payment from CSL associated with the first commercial sale of HEMGENIX® in the United States.

 

  ·Implementing strategic reorganization focused on advancing multiple clinical-stage programs, achieving cost savings, and extending cash runway

 

·In October 2023, the Company announced a strategic reorganization plan which included a reduction of 28% of the workforce not related to manufacturing HEMGENIX®, the discontinuation of more than half of the research and technology projects, and a focus on executing across four clinical-stage programs. The Company expects a total cost savings of approximately $180 million over the next three years, which is expected to extend cash runway into the second quarter of 2027.

 

 

 

 

·As part of the strategic reorganization and the significant reduction in research activities, Ricardo Dolmetsch, Ph.D., the Company’s former chief scientific officer, departed the Company and will remain as a scientific consultant through the end of the year. Richard Porter, Ph.D., assumed responsibilities for research, as well as non-clinical and vector development in his new role as Chief Business and Scientific Officer. Dr. Porter has more than 25 years of neuroscience leadership in the biopharma industry and joined uniQure in June 2021 through the acquisition of uniQure France SAS (formerly, Corlieve Therapeutics), where he was founder and chief executive officer.

 

Upcoming Investor Events

 

  ·Stifel 2023 Healthcare Conference, November 14, 2023 – New York, NY

 

Financial Highlights

 

Cash position: As of September 30, 2023, the Company held cash and cash equivalents and investment securities of $658.9 million, compared to $392.8 million as of December 31, 2022. The Company entered into a royalty agreement in May 2023 and received an upfront payment of $375.0 million, and collected $100.0 million in July 2023 for a milestone due from CSL following the first sale of HEMGENIX® in the U.S.

 

Revenues: Revenues for the three months ended September 30, 2023 were $1.4 million, compared to $1.4 million in the same period in 2022. The current period included an increase in license revenues of $0.5 million and contract manufacturing revenues of $0.4 million related to contract manufacturing HEMGENIX®  for CSL, and a decrease of $0.9 million in collaboration revenues.

 

R&D expenses: Research and development expenses were $65.4 million for the three months ended September 30, 2023, compared to $48.1 million in the same period in 2022. The change was primarily related to a non-cash, $8.8 million increase in the fair value of contingent consideration associated with the Company’s acquisition of Corlieve Therapeutics in 2021.

 

SG&A expenses: Selling, general and administrative expenses were $18.1 million for the three months ended September 30, 2023, compared to $13.3 million in the same period in 2022. The increase was primarily related to an increase in personnel and contractor-related expenses, and in legal fees associated with various corporate initiatives.

 

Other non-operating items, net:

Other non-operating items, net was an expense of $7.8 million for the three months ended September 30, 2023, compared to net income of $11.3 million for the same period in 2022. The decrease in other non-operating items, net was primarily related to a decrease in foreign currency gains, net of $14.2 million and an increase in interest expense of $12.4 million primarily related to the royalty agreement that the Company entered into in May 2023, which partially was offset by an increase of $7.5 million in interest income earned on investment securities and cash on hand.

 

Net loss:

The net loss for the three months ended September 30, 2023, was $89.6 million, or $1.88 basic and diluted loss per ordinary share, compared to $47.9 million net loss for the same period in 2022, or $1.02 basic and diluted loss per ordinary share.

 

About uniQure

 

uniQure’s mission is to reimagine the future of medicine by delivering innovative cures that transform lives. The recent approvals of our gene therapy for hemophilia B – a historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology and manufacturing platform to advance a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory mesial temporal lobe epilepsy, amyotrophic lateral sclerosis (ALS), Fabry disease, and other severe diseases. www.uniQure.com

 

 

 

 

uniQure Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, the Company’s statements about its cash runway and its ability to fund operations into 2027, the Company’s cost savings related to the recently-announced strategic organization, whether there will be continued progress on the commercialization of HEMGENIX®, the Company’s plans to announce follow up data from the U.S. and European Phase I/II clinical study of AMT-130 in 2023, whether that data will help to further guide our ongoing clinical development of AMT-130, the Company’s expectation to submit an investigational new drug application for AMT-191 in Fabry disease in 2023 and begin patient dosing in 2024, the Company’s expectation to initiate patient screening in AMT-162 and AMT-260 in the fourth quarter of 2023 and begin patient dosing in each in the first quarter of 2024, and whether the Company will begin interactions with regulatory agencies in the first quarter of 2024 with respect to AMT-130. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the regulatory approval and commercial launch of HEMGENIX®, material changes to our interim or preliminary data, our clinical trial for Huntington’s disease, the impact of financial and geopolitical events on our Company and the wider economy and health care system, the Company’s ability to raise additional capital to support late stage development of the Company’s clinical program(s) if supported by future data, our Commercialization and License Agreement with CSL Behring, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims and ongoing litigation, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company’s periodic securities filings, including its Annual Report on Form 10-K filed February 27, 2023 and the Quarterly Report on Form 10-Q filed November 7, 2023. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

 

uniQure Contacts:

 

FOR INVESTORS: FOR MEDIA:

 

Maria E. Cantor Chiara Russo Tom Malone
Direct: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558
Mobile: 617-680-9452 Mobile: 617-306-9137 Mobile:339-223-8541
m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com

 

 

 

 

uniQure N.V.

 

UNAUDITED CONSOLIDATED BALANCE SHEETS

 

   September 30,   December 31, 
   2023   2022 
         
   (in thousands, except share and per share amounts) 
Current assets          
Cash and cash equivalents  $229,484   $228,012 
Current investment securities   429,428    124,831 
Accounts receivable and contract asset   1,644    102,376 
Inventories   15,654    6,924 
Prepaid expenses   14,884    11,817 
Other current assets and receivables   2,532    2,814 
Total current assets   693,626    476,774 
Non-current assets          
Property, plant and equipment, net   45,946    50,532 
Non-current investment securities   —    39,984 
Operating lease right-of-use assets   30,360    32,726 
Intangible assets, net   57,976    58,778 
Goodwill   25,273    25,581 
Deferred tax assets, net   12,351    14,528 
Other non-current assets   6,018    6,061 
Total non-current assets   177,924    228,190 
Total assets  $871,550   $704,964 
Current liabilities          
Accounts payable  $5,584   $10,984 
Accrued expenses and other current liabilities   28,427    30,571 
Current portion of contingent consideration   26,708    25,982 
Current portion of operating lease liabilities   7,888    8,382 
Total current liabilities   68,607    75,919 
Non-current liabilities          
Long-term debt   101,431    102,791 
Liability from royalty financing agreement   383,711    — 
Operating lease liabilities, net of current portion   28,977    31,719 
Contingent consideration, net of current portion   14,030    9,334 
Deferred tax liability, net   4,917    8,257 
Other non-current liabilities   1,093    935 
Total non-current liabilities   534,159    153,036 
Total liabilities   602,766    228,955 
Shareholders' equity          
Total shareholders' equity   268,784    476,009 
Total liabilities and shareholders' equity  $871,550   $704,964 

 

 

 

 

uniQure N.V.

 

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

 

   Three months ended September 30, 
   2023   2022 
         
   (in thousands, except share and per share amounts) 
Total revenues  $1,407   $1,449 
Operating expenses:          
Cost of contract manufacturing revenues   (1,006)   (861)
Research and development expenses   (65,400)   (48,068)
Selling, general and administrative expenses   (18,074)   (13,324)
Total operating expenses   (84,480)   (62,253)
Other income   1,424    1,485 
Other expense   (228)   (199)
Loss from operations   (81,877)   (59,518)
Non-operating items, net   (7,763)   11,332 
Loss before income tax (expense) / benefit  $(89,640)  $(48,186)
Income tax (expense) / benefit   69    329 
Net loss  $(89,571)  $(47,857)
           
Basic and diluted net loss per ordinary share  $(1.88)  $(1.02)
Weighted average shares used in computing basic and diluted net loss per ordinary share   47,770,101    46,772,430 

 

 

 

 EX-101.SCH 3 qure-20231107.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 qure-20231107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 qure-20231107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2330023d1_ex99-1img001.jpg GRAPHIC begin 644 tm2330023d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 07, 2023
Entity File Number 001-36294
Entity Registrant Name uniQure N.V.
Entity Central Index Key 0001590560
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code P7
Entity Address, Address Line One Paasheuvelweg 25a
Entity Address, City or Town Amsterdam
Entity Address, Country NL
Entity Address, Postal Zip Code 1105 BP
City Area Code +31
Local Phone Number 20-566-7394
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, par value €0.05 per share
Trading Symbol QURE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2330023d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001590560 2023-11-07 2023-11-07 iso4217:USD shares iso4217:USD shares false 0001590560 00-0000000 8-K 2023-11-07 uniQure N.V. P7 001-36294 Paasheuvelweg 25a 1105 BP Amsterdam NL +31 20-566-7394 false false false false Ordinary Shares, par value €0.05 per share QURE NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://uniqure.com/role/Cover Cover Cover 1 false false All Reports Book All Reports qure-20231107.xsd qure-20231107_lab.xml qure-20231107_pre.xml tm2330023d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330023d1_8k.htm": { "nsprefix": "qure", "nsuri": "http://uniqure.com/20231107", "dts": { "schema": { "local": [ "qure-20231107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "qure-20231107_lab.xml" ] }, "presentationLink": { "local": [ "qure-20231107_pre.xml" ] }, "inline": { "local": [ "tm2330023d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://uniqure.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330023d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330023d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://uniqure.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-115011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-115011-xbrl.zip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

N6LW+1AWU+JN7 MC=YAWQ9&O->H776;E\U&#U5;==2XJ7VMMDX;J-:^N&CV>LUVZS#3KR0RMQD) M'#(+&V',P2P5^30!Z]?5WM=FZ_2RW=I%]70MO;VER/F]DL<:[_S6'+[7')VT MNQ<^+2$3/TRX+F(/M+6=$.)1K4X<"[<94'6$#S%]5 M=9 Y0-E2;N\SSC@/K3C_76*9MH-V@N\$@]LDS$'D 2"1+9J)]J7,4Z#*\OHK M+:V_CHC-&E[D%K\02;W V%GCU+TA:RU$KT9SE*)3IZP!]C' CC0\FP''Q(A; MJ!%F4I66^4!XJH#V=Q%'_"&6;V%32KT\,UE_9KRLJ4N&E/%2E\-SXOB)V2_^ M_/HPKA.:?Z&!C".5JD $]AT".M1*_TB_A\CC);33F&)8L)PE3^L#)A%FJ&<1 ME:= &J+&]E8-XE'H\^7ME,#!?9T :[H.PU=%S5E.B>\6UK3@^]I$0_'A/.Q3 M35W'%@-3'OPFR@Y.$#X?.EI Z('8#N34>B Z""?G.'/*GVLZ#MEW')=@/I=U MLQ'1S::AFC98&9'-]QQ8JS6O\%@SM015[77N^Q^7/A0(]I_MFYBW) MTGM".:$Z\0HO\1/4[?]DUFGI_B[[TFAKF0ZO762E7$$I[?U/R_DX(N>$:M>M M-CV/%[SL/'2^/W1J5@ZD*8KI1ZER^:9^4RXO"F1+;/&E(-&IY)7'1)TT5(&K MM#+5N5AC!0T_[+6,ROJ"VA$+CT=G;;[<@CSM&T1E3*,BA.-F/;)6O[Q &5Z@ M 2\83,TX_!0+B>(V]N/R[;S6X/-<:6;LX6,Q#53M0RTU_B5",C7%[E MO3+1S^=@]TIO8T"JFF83QOR/.Z&.S8U5&IA'36F1'4=^D!0>P!. M@K#->[=GBO>EPX)5CO@R_PAN[6V(+'+AO_XH*MG] P9@.K%&ID&0(6*274B, M5=WEPC;!L&(UD%&,B<[[=H%;F"I _B:)Z^*+8?VF4RBLE\0M5GR81JKR M=RZ;L,*E92;K/I/G)FA(AP_T=\G,P!QVOO[L$J=*7\CH,IU419&E?*$@[>>> M2&?^S?K]ABHO)V# B>V77FSD?_7-!6C6 -5$157;WNJ!FA%TCIGCUR4W5X1Y M6PEX>V]RS,Y=^)EOHJ*LW+D, NB9_Y :/*#F=@RL6*I2&Q'U'O$2-+8LV[1L MRM.@OCE%?:*;$RX\:(3\ 83JC:4HG:$!U6&E(LI@V3H$,&J\U,WHV-4=;!#3 M9?H,,8C8V6 FD/L=S#ZPA(-DBC?8BSJ9"WALA(U9T#: >-><\'Z\@D)Y.L.V MMW8.:841?N2D@DZ)06SP DT#<+A>EE9-*VF/^2_E#U@S7YU(FPY'WJRMSFR< M]QC@,=5G970-DN$&DZ56;&2P:W5M4P?FAZ>#KN&G4"S!6.Y=GF)V[!3PRZOF M?=/4"3;$D:"P=8IEPQ-I\2#1.HD/3^Q)/WW$P& 8\_:6%=J X?O)'O2>DO>5 M;&G+A>^T[&3W4>VDBY2-J$T"ZP@-0]MDL9D]["454)*$]F;^P8;(O.DR&AYRI@CTMZ.&E9&[SA"LC;Z/?X7#%TH /"B4&)#'&NMGMU 6;X @Z@4 M1/*&<>7'+"P_=<1O,J(.D3C'A!\]G]C8>K+^](H=7[[K%)R?\3X)5D?>;ZJ. M&2L_67)[%L?A^OE31;@/)B(;-:P)\Z\D:UL! KNK69VN?]7W<;OPXGU-B(^B$A+2YH>A"G)1\Z.3R?%^FQT3>Y?=XP'"*WN!\6QD1+G MD5J8:?@7ZCDF&+P+;-\3!YV?UY*FQ-^/#/4\U=G_@C8NU M?A$R56D:&H]*">K/D"J*C]#K'ER!V$9;K@E2AD #(*3EB(?;6T/;G#@C'MU: MO%"(&=+(@!KB8%VXT@-6Q0_7ELH\WH':'-KA@/L'HMH3 ,QF$B+'\WC=>10 MG*ST)04]\ZSN'#4/E_V.4>3I#Q@\SQ$V?%FC)5&_*"FK1_9P ]2G G/-0QR_ M;D]8]NK'S=EQ6]M\5>DWS#PO%?NXTY>TY@;A5;0TLWSK+79)!J7_T'(5L46/ ?F+QO0L*WQFB[? ]#B,[0@G=W!\W/U*U65]#-5V)_C MYZO[NP$%NAG5Q3C-W/P=L]0GL'<7)>#P#V ME\MK0(#28UP$9JLR3$S)PMD'OYNSDH 41&"VE*VL% R#RX[+Y"W@4NK;!-]+ M?0)V 1C%^@3/6)1R(8:P?U-H+4>0#/U00W[('7[:W*"_H:@@C M2QQ/LL%!8G"*V## BZEBGQS$N7!OMB]@[A8YWE^NN Z"//?9(Q C"E9R1AZXCVJ8-* MI726>U$1G=9/BM+9!XY7$V:49U+4F+]T)S3ZWRXH2NBX"G3R#A@$!*"[1A0'6B^;H@9A0(6"8C8OW,Z\?% MF&PD+G?8W=Z"Z<%C3Q7"6A>&#E2/1T\FSYHF$$ AYO;O>+(H!D:03G&?ZAZI M8)L).W.6N$K%#0MZ][GL@F/N_- ,A(7SMTWP Q^F"-^"(QW>P/Q5D;R_[B=> MNV@QP%UDKFY^[4(DJ<(:X' >@WT>7 J%UF?;6PQ2:9 SQ)# %O/N5:D1_D 2 MZLAG[PU5][-9_%):SL9;_(5=%Y<@^/Z19_#]5< ^EY5/57:T+P'OGWG^G]BI M>;EJ9/,)-?3 [+7,=,(N@8>@F(2@3IAJ4\L+#2(*LRZKZY8,!%_GEG93^?Y;'4B 3[?3/CE4ML+:K:WGAF&+V]#\+JGYNHS MI&*7URI%YN"]N<*/F!FP!@T06?-DKT\@\6J6\XJ^7?,[QK/RL4QG]J'U.53(L@[X18YI'>5S'Z_E.;Y;G3W43N]<_"WW[=PIU;_FQZ0UN&:7 M9^Y-KC3\;N6/'XN/IT77?GCH=[HG)ON9/VWV'GN#4^TSG=Y<=^Y9NU#/U.W]P<^K>]43 MQ_\!4$L#!!0 ( .T[9U<[<)GC<"0 "%H 0 6 =&TR,S,P,#(S9#%? M97@Y.2TQ+FAT;>T]:5?;2+;?.8?_4,-+YY%S9,?[DJ0YSRQ)F"% 8]+]^M,[ M9;ELJR.IU%H@G@_SV]^]525+MF5C>0$!ZIENP$OIUJV[;_7IZ^VWBZ/]O4]? MSSJG\)/@/Y]NSV\OSHX^O9<_X=WWZNU/QU>G?Y+N[9\79[\>#+CM?R#EDN.3 M6\-B'KED]^2&6]36Y L:Z3+7&!S %^&KU_'O%3SCWTQ^^2.QJ#LT[ ^D='#T MZ?/5Y>V"#QXV>6#KS-O?NQT9;I_\%E 7EB 50#[Y;-C4U@UJDAOF!:;O MD0QM@=I]\A4(QT3B ?AO&'Z5G'#+H?:87+M\Z#+/RPK$&:+'\Z/_3 Z^3SZ? M=O;W=)-1%\Z:$3X@Y_8=\WQC2'V#VW#X",JI&PS)X?GEZ3M"'<_O^88)G.\ M,?E/AJ .J20S /V'7-G$!TS^(#[?WW- M[!8)LN59X'*'49MBE7LT8O7P/;-^RAS^VWKO=W MP#^"2.D;'L,-F!1%(L#KCV"K/'#]$?E;"4K8D)"5.14MI:)0X0!Y[.^=="_( M/:!3(.[:-7Z2+[ BL\GW;H?0>PIZ" 7+U[-O7\XNS__W4_?[]=%;EPUA2_AK MCNM59;L'G.NSH:'O[[F,NT-J&_^6@MOG@&(] (:T">W?H9JWA\0")6\X9L3? M!<^G0T8<5*;4\@1WLY\.T_T,[1CVTF>F<0?<^*;<*NWO689IXB:!-W7N^<2C M=[ [V"M^!'G8AL? +RYC9 R*S]L-13U/ZNGZ+@=2T*DW GG//<-7J 2][_*? MA@4498[)FP:H_!#15 CV+G- Q?8 Q]62)IE;T@I0(IQ1AG8Y"(".046Y@AE MTALV (B4X3&=PWO3TKWYXNGCKP ,OL%X.40?@9M,[GY V=WG]_A]88E?L)]2 M]\Z0D9T+ _0UZ>6)K!ZR>"_K@GO>!H:Y.026%%02E,1RENK#P3WD83; M7(Z8[Z$#\^G]]R,R]>$$$"^+OQ?W]PXO.]W3SF\?R&_?;\[>:802L'G[*/6& MS&8(IDN=,6Q1^@^14 09:GN@CX#P0<:H#QJ :-11#KP(5.?! \$H\!A(& 8& M9U\81S9CL&&@_3X=$Y>!\0FL ,0&'Q],7"M7N5:X&N+*%W[8K'F!2!V%W@[P MDRN]'4=Y.83J+HBL5TVE-H7?PT+ C+@.N-LA%)$%7U M_MX=-0-E3P-T8'P:Z+3X"(8A_#(+R4U[ZXH]@(:G2 [ $=^H[Y-_40=P0#6B MCPPV /'+]$!0+1_ 7B0]Q5BG2!0N_@#+# @7J'=,8 =@] )* *X1A>]27.Q. MNHIDRE-$_(%/..L&SOE>9('KA0@Q.?^!"PBS#QX)J/,-BK9XR%S[>\QVN6GB MSD,K//(L*. @Z(]1!WE+6[2HC\$UW/>GSW9 MA(<33P].BT7.A==L3FA4H*>90! 2HO:4Q@K MM\OXI<^T!\A2_D:1X'&8'I_#C72_!"S4YBB)YCPQZ:L 47L3&2*("4D6]#K' MK<5V@+A#63;ME\T[0R%L@,61H8] W)DF?%(W@SX0;> @=)5B79E3L%J(O@$< M'+\O!$Y1D6PV1$#FI%''0_IT0$L C4I2 \%?$U3K,HO"J9B ?U<*$&!&("?% MWDCT4OSC(:.T *0;'$]A2K4!]?0#W0?3SNX;2"Q*:R&13J29X'4DDI"PA-// M!P7X/YA&.MAXR&*H OOF>)K;_GA($RNR5OL!56L9OK(.==CV(#!A2< R'0H( MP'8'3#LNT)CMFV,@>J E7;*G#@#XU-04F_$ ]*+\/D,1*C\4^C\H9$=4[)PP M>R3$EQ*T@&=O!,\><;//@'0!+O@04+8+Y YKP(+Z")[+; $3G/G[YY=># MTH'XNWO=.0G_5FO>&WU_A.N5?I'9GS2P%WSN"/@G+_2X[W-+O ; W]XL-,5! M5?O"QE [AI4.5#[MT^WI#'2E8J5NV-%^;T5N+?K8W.HSWYO'XH""[S?^0+IC MJ\?-A+R7>.&>H;GZ@=AH/9OP?,OH][D?81P 60;&BD<: O, SE>#$;RN3FC2 MJ?SDBO^$"G1BR8,($>8:"M;%*G7:,4:,O+^]P?\@&6Z+.90P_J]*&?_W^OAB M)6*7M/X046[*&QEC@X.C"S09TY'ZTEBX]/G#1)P#;K\7&:]@ B1G#_ [F$%( M!\BB=,.\7:LI+E5$-^LE@H68&,46:D$ *("H'1P3/@=K)E)3$!A"?WV M@O)U[@M][LF- D^.P%:#@P$/!,-DX*>9XV)B.&/"M[YZ>_Y[TA'(E01PU\+4>=\%TG+QV;&*VK RRS@,SO ^<.@.QDF(1=)_>PS,3 M'M\#@OI1Z#%0* "C(V".@]1(@ C!3/O(&&+>(V8D,G*C+%<^N[?!9@5<)Z7< MY;YT7*O52.Z*J)7-[TF/,7LBEH6O&]IH2B#Y]YS$15 HLM=41-\CU2;SW45R M&U.%,F@+'J4*,T6Z(HHR$1EDDE%@"55JU2S#,>5*A)&%8?5U;08L!D@#U0 - M!9%$#VM+F-0&B'V!=IU;/<.6V4EQ5 X\6N5H[C ,:@4V]P+'P7B=C.?!IU(> M4I3TC$4);$;= M@OUB*=&%-,.S+/$Y@LM]ESL;F8_\[M]/;IP' ]?\98KRTP MUETTC>#3+AL&)A6A? .3JU38@%'@,!T4GS'FCMPERLDZ?0L$H8C1(=,??C[M MO,-G@U\,3.I-!'$H6X4IB[\[W >IAJ%WC';++$M*JYB!K2KI5US_.MC9L1Z!@)3F6/D]<--86(+V&"289S4,4@[Y#$B2[F%GZNJ!RE< MYH93FHQ)8=254\N'[K?;B[-WR 'DK2V+2V3&/ZWB3"C'F%::=%)O)SDOEB 7 MJ:3I:FH;$-<']9<.#%EZ':(DGOV>>!PR#:X"7H#M(NE.G JA-96K$4^F>^F@ MB)=S]1@PS@-%L<)*D&9'^'2P]T5V'0P-6R[$=3U8,_R89-#L6G7+_R(SKY<. M6U;4E8O %RT"RXW*%D0@%I@0:HVY[W)G9.BRY ,% (@>%]C+(X>=BZX4?044 M>O^D-O#(.!)=Z: (Y9RHKF1]:610,@2!BV+7T)DM>)H.0=P(*&6HQ0'8C@TN M[>KCZT*Y5-%$6&9[N/ "AV%1:I^AUV %/LK%,CE$'+TC@ 6L\W.IRS11"@%T MB^M80DI>=$5T9DU<"$GHQ0J66$(L)ZUT3.G$)(O2)Y6.N3V8"\,5A6&[O 4! M,%4X-V7LQ0.O,6X5U7A^6(9GK&$1+N!F&3149M&,M2-[7;+)?"_6(,&SRD#$ MX7F7PG0#!PL*4P28"OD,1NYJ"4N+D[(H2H'AM=56>F[ MJ?@"]4/6 L5FL)3^.R8@C3L5J$CLONRH,GCY%"R>Q5 +\.TQ9@.N504QJN(; ML*K?7[G."#CS5.K?E- LZ_$L+A84]]AM9HOPBNBWD?%/ 9?-+95"3 F*V# X M3N&.B^1$98WAG7*[69(1GSBV.K(5!%#*AS;0!E9?^YZ/M=5"X]O\3D"2/HWL MZ6@[8/.):BZ13A6^9> #A_!@@(S*# G[.S#NJ*GL(=%M!;1F(JS_9A.CR30& M*,JN0#.!?#B?_X9F.,9Z3N1A92\@2.?]++"3Q!U M*& <.A:,)\H345!3S^.Z$163I'<=A$L>LXL\8-S45E$&W8A%1NZ+8TH\Q0PX M%9EC2' 5SBW'%)HJM;,P&5- 9J84Q'J=5F^SU*(FIG1@Q&<%:&K4@<^D/L=V M>.(&]CT=[]X#4:JPDN<81D M_$-LD,A$/\&5T<+VL..Y9-)FI#G^*FBCV*)#=..P&40$Z M WOV90@+IS%)=*(2*>+&1AB'O,:).6Y*K"@4@+,>6&)2CN? 8PU1RA^.[0EQ MCQ\C]PP@AI\VMPN3:BKL5D ]H>*Z>'D(^9Z(\,14QB7BD(\ ME9[!'3@0B^*D+!D.%*#_Q0VL/ A#*K#6/P-;1);+4P=,];\#(YHD%G[^LZR3 MZW:ZY%!2ISG6@)A<$^?-8 ;7I0X#\TGWWJ%A@;.5T#ZD'@[("&S8@P!CP;"; MR"IXTKCE3!?BSJ>&'1]]=W0,A _5)%<@X;,[; /:Q2S80AHFPJS M"Y3-S'0R2*2;OC)J^B.<]0)L;@^ H4$ :-$XN'(MG >GJC@0IC_!'X3/_+DC M/GZ(0IY@T,H*/![-YHZ&8&>'OS,TG?!D:I#E!S%^L+-@7N5T'&0$WHAT66GH MNT;)-JF[HY%LZ)D&KK0P8.TWC7JKV []94TF;%TU5>U-M5TIMF:F9YXR70%3 M%L!4IGM'9XHO73X&3AK':BY!^7ZCXZ@6*F7*S-LP?&BN+OA/DOCUI,-@3W53%= M117O M.YHHLO?#.,14Z&> F[5%8I8P!/@8P\"E9;Q(2"_&T<=>[/!!IGOA,! M%X4F 8[D[VZ;Y"6)$$GWB';@N3#HV&=RO_M[$M!V'(O(VK3'5:]EN*6<[N/QI^3M%UHQZCD%2,,<,&M5:Q'#M!T!Q+& &' MU-E#X1L1QS4 $6#8Q6/G5+JWH,0T\J85TSYQ+A$BFQJN&HXGYF>+?![N$YUW MHZ]F)N_O)23#YT(.,WY?HF>GME'.27&>%+M?!"UV9FFQR^#L[*&FYL;*: 6- MM5,#CF?(LARGIDW(LEPM5J,1ZP_(YXBZ%A/F- G"(AZW;69.263N%L*OA/O2 MY%T"*-O9$% P8%@O.D.4=_ X'GBPCHM-@CZ;3'B]RX5?$L5=B2D=*"K4Z U, MHH,NPK2ZS?P/N[].9T58'P!4T!M.^Y34(E1W,R;U-N 7!THEEMRU7*Y6(TO M^X"<#I4TOLKG]T!FMK! EL=7P2EAJA"#SN#'PN*BLG,P M\ #NWG@*2GE\];A!,X%:G04H9UN6BB0Z93@Q63EQ''.Z=C]G_WGVOP34F]SS MLL/GMR+)+*&*V&M%MD6">M-J%QN1I\'QDI!BJP5&MX<%MFC,&6: -"T>X6!6 MV>T;-C9,BLG LV99,S*L)8^%H"W2A.%#2Y75'YH3YSQQ=GH\\,/D@32$,@%: MAK"DD!-=815.GC?45!\YT9%)2S_P,0N#Q2YX806^#&)77:43+V(':Q+$:#A$ M>W(?!C&%%274FKJ/0M27W*F+OL0M"6"@"I85$\B124;,PK9ETZ#D>!+FI9@H M RL/F4/>-B#$=X^JZK\H 29T'U[0((9!Q%RR2>8N[IN%Z[L,QX:)!!X%-/\% M<$3QJTF_+,;[Y-!T;@$D$ZS@\H$W"L>#BX1>U(4H]@Q03]\' KA!% HK--JR M'.V/U(M]T*9H7Q 3-A%7%N\')I4I+<"A&-$^566$;TR'%QS0QN(HT"J0O0( MWYJ!?C&KVS$<( ";R2G=.,C?Y:#^F8^B*39.WHB'?>(=F=,WHD1CC_\[=H? MJE,\P(A9H=%=F^X"E>$0:5NI"UG4.U@Y_?WH_OZ^J/BD"))]:ACYHX?Q%]\, MNJ12J)I7"F6\4NBI5.0DLR[O#"E<$:B<\#:51)X77 ?ZU[<#8+>6%^) M8W+$V$ET?X0_@G$)]++"RUD*ID2TO(]'X+E(.J89^UM))*'$XJ\.)JH/@Q@8 M0<;LZ.)U029*OXD*W>TS='CPOBE4%J"_<9"E1[P /^&1MV '^!\I"&'= ,G, M-/F">KW'1#QN^D6=!V9_\I)L1P1-27NFX8TF%P_)]W&RD14MN[^G7A:EG]/+ MX@TCTZ^@!V?WIU^;N?%&OJBI-RTZGOXT%B'/O!*.!IR!"(X/<#0#DJK:G=FK MQ]B/F6UZHRF M@R+> ,TI#FH@3H8-_1^&I/9.IBFFU"'Q,7MVQRO M"18I5?&VF+LJ;JFUC_MZ2K*QET,7M3Y(=#^%0RE<3'TL],Q4P8?9\\ M$$S=[!0&7L+=@3TOEA8['#'3D3@7PWKW]X8!3M:)7QV5:&7'A^PG[4R* QI> M/!J-X%@T&RU^Q[2\"VG175GAG@0VELW>6 FRQ:-\1* YO.5+W' 877>V9,3/ M,J@8%;T3RT:SBGK*B!*CF)HBR&$8!YL:RQJ;V0K,;^L&\Y8^)_R6N(0 T3 9 M@GJ;F-/Q@^C:0DQ\@M2#XQ@,8$74!:X,YBEBQ>':D?H)6\N72Q<\<$L.S*8> M;"MV=8.<^HS"0T@;Q:VNX?WPDE-2<60HYU1E%E(,I] F&U-Y-N%-?4%2MS:3+J>OBJ4O[*TY2V ?C8>V5%MVN ME@@KTHFHK0GDUD&A 8IUDQJ6"DV'$A;/=ZCH.E:<+&@9R1P[F'7X-IB?HM@H M7@L9Z_\[?S!T)"A&7%BB+D:5MLP-/!6$KEA;63=*FLQI M,!'V!$<]5@LU,$S93QG=OH(:OF/;B(D;<2DJ$O%GC&*42X5_X3>P3NHSZ[ER M:EUX1VQ(V[])\04R9O[KO\FOSUTP6R1?C#L6RI[5$*F1,0_V]Z3Q)RP<4-&@ ME0%3 0H6TY!C/A^6:-H$]@F?BNITK#DG' SKX40%J:M:$E<$6&)+H@! UD&E M&3< >PSS(5[,$ R%OV"K*+)\GCN BSWH$_3P=#]#F9"EZ$I54*U"0$+&.1X\ M(/QM4I6,M=:RUCE6(#U;#RV#.(M+HNM1O7:/ P>M@J8X7DPV@&U_OKHAYY>_ MGW5OKVZZ'U1A]:X?^.WL]+SS(:HT%IB(51OG-/ 0#:0\!O7,2AT>^8V"I43. MBN0$#$?N)A_Y!NN?C SJ4G(3@+FXS<7KB*];L'J_49/;;(9Z=HW#E09T>/[8 M9.%\C@5#.TX-<)3]#Q*::K5=:#=+A6:]VHC7W^\ UM5!(XURLU M-0KM M*V>(!%;8P*?O1U91%P+W?Q9EQYX,NP"<7G117F<2-K]H"8F_#+A'-B-6O_JP MEB<3=Y],U$417(8G9*3J\ONU<7Y M:0?^V-\[[EQT+D_.2/?KV=EM-T.G]ZC.PNK-N>N[%?-82&J,C7IP5_AJ"@TQ MU=P;0G9RA2B[_/6@1GIH= M:9*2D%.MMX.36Z[T-XK A">+(=LGV/:K0W+E*9#\-+RT4%9U//N#GN'E5)-JU1; M6J5>?[=Y4F$^MW.BI@50SV-8"OO Q)S$$UX47)U_6C+I+?VBB\&EM;Z9XI'/ M?6,;D=D?^ MKTZL4FEKM59M=>A7)YAG@X&65BK/F+]SPD<-8% M=[$\2;^B.NX:$GREM9TUMP'EL\)>N5+36M7RKK"W$]&_"7 =71>VE9JW)>JM MIF8)"5/C=1R]UJC-Z8F<;5;#7:FB59N-3++-%C4.7E. =:8:B,@EA/+:BF<;1+3;IX8NL%:O;I:OFC[&\M/ M:?53:I7GQ.E.3VDG>G0)Q!N$?V_EI4A+@\";/WD;]+;!)C&QIK[:K6 MJ,RY,+LYR=1B(C^[I3&O9D-K-M/(C2UM,O,9HTNWK&7M&JCE//, M>LBK:,UY+R\3/+-CC7-N^]0>&B+#*YCE]=AH]:;6WEUV\J4CKP6^]<[J29Y4 MRQP&\C]/(7L5)5NI:I3G7F)*SP:K(J[>R61BT8\5QR@;,%?<'T)^O3G64 M*UJUOK-C?^G(JVGUW94B/G;F9I.LKOU@'#;/$:Y>5E,JSQ%5GLG-WBDUYN1F M=C.YFQ5\;)S4W4@^Y,G!I4JHV4RJP\L3N\_@[+!WI=R>BW5E/+&[JFU1*=:W M OBG8R5%0LEQ_&##;.S1RX:NK$QL8CW2YT'/9"LU%,&#WB0!NNGJBG!@^5:S MK-7KI?6QL0#L&?R\;B0W066V&[6=(SGSA19AXYEIR 'D"S)X+Z@@X<5N+'.) MKTF3ED/'6 6\:_S/M9RN@GH,CR7F(C-!4FMMJ5Q:E%]](=VR0%AN$+N4.C9$ M7E]-GKVXD!48G+7*SGH27CCRJB6MWLQFC'P7F O@;?X3/W/$M64AVE7);NFUFKE MP?2LGU)+J\[+ANP&TY^R+6H]J9"'89?FJ^D5JI4UFJ[&Y[UXK%7T9KM;$9/=AR' MO##"6UO%M;LN'U,3_Y#7QX+#1\,[4E\%)51;5:U9SOEH/>SMN*AI&:UM[=3+L7CCL4Z/D\P,6=(WG&:PNY ME+)6:J]V.U>>\7JZ4VI7ZWF^:]6.D3SGM?W$2;U:T\KU)\BW\=F5ZU7P M5YY@EN-S;D'+A<@.$N<8TV_D0T6?X]EA[UF[GL8*R8(06>[2;P!A%Z_B&\'W MF>O]MQCTZ(]?>$[YQ6[L.:LI;P4ZS&7>VA7<+:TYW_*2ZZMG<'8X!+M4>FZE M7H_=*SUGZXJ>IW6$RCH0K4&:\VVY&^U_KA%NMP\- [MA+_;V4;J^9)EZVJ.= MW7H[VK"3>^TPW-HMWEN-R;V_[1Q?G,'O^WN?KM/G!2SJ#@UX GZT-/W0!Z\B M+R4T[*L+P*\E0/\H%,AG@YG]#^2:#@'A79 ?S,8[J>ND4 A)Y?3\]W!]"4_! MYPX\H((84Z^$>&S@:\LU!@!U/;V>V%^$P&N $)Z9\/B>R^B/0H\-N LP.@+F M.$B-!(@0S+2/C"'F/6)&(B.+1_A$ 6V\5O@,G)9_+VX"[ > B%$2":0\?VR M\_WT_/8,[Z"_[%Y=G)]VX(_]O>XM_/QV=GG;)5>?R=7UV4WG]AP^D95S3$:B M$%CDY.SBXKIS>GI^^>77@]*!^+M[W3D)_YX6XF 1F=3Q8.7PMX]DKF6-)MXBC-5;P'(K2R^;W+G4^DH46Y"*/>.T%-[6C3JX0O9>_'C1F<;O0 M[DX$< ,#)"2:VY'+&+%@H9%'F-UG??BTXS.KQUQ2+6E/@:C5+?55??KYG:], M&:G6VQIA5%8FC"W00*5462W1O-UMOSHDK]89N64D/PTO+=1%":KH<7"2$J*E MY+(%1/F1/031)K)@H0&RKG6U(T-J5X;2H6$3?\0#C]I]^"3[J3/4 M#QB0$Z$Y!^PE]9/XIBE;4:=K!O!3<+]C"#K1S_,_BOM1\7_]G,HT?M M6N'4M0\O/-O\8C>6[38FSP\'DKE4]PE\*QC +X&+M!=IBU?05G!8UDJEK5[_ M-&>#O$R\M>8G^&\!:YEK6;IA'J.N/A+V9A\XP^3B$MN)A'X=I]VH@XVTU2:_ M5\(FM996:FQU[N$V..4I6I:ZS#1A08T,F0UFCBDXBO8MPS8\'\V>.[:0J?+> MF-7U&1!!BGWAR&Q40*4MN,ERP;7+RK-D]LS:TOTN4 MERH&P1TJ"_R=A.4]?,1F \-/J@C8!G3;O&1ST_J8&!UEK:>568P>(??@,GX=Q ZQ%?8_>> M93XM;[,CJE8>]XR>L8%RR7QB@I&2:ZBM:R@P-<3UGUM%;&YC/*:-T=1:]<0R MZ1V?X#,:O_GHNBIC2:4=[#]'PE=Q/OG]\@VU.KKSKPJL'VA#^8+@OX (* MC\/9*H+N/1)X\)IA$_"$G4 $Z7N;,DXV&C; ,FDV2UJYE%B1_LR[46H-V%Q% MJR5?L;).1TIL8E)\+LIDVDF:UO+2XC$G2V8?-3Z2*T>D7C^0"^KYV1F%]/!< MHF5HBA85WWE_?'7ZYQ'^\O7VV\71_P-02P$"% ,4 " #M.V=7DN' P"8# M #@"P $0 @ $ <75R92TR,#(S,3$P-RYX&UL4$L! A0#% @ [3MG5T8G<>54!P TU< M !4 ( !A0X '%U* =&TR,S,P,#(S9#%?97@Y.2TQ+FAT;5!+!08 ..!0 % $D! !"30 ! end